Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUR1900 inhaled itraconazole dose and duration study in adults with asthma and ABPA
2022-002289-33Phase 2Terminated
- Sponsor
- Pulmatrix, Inc.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pulmazole in allergic bronchopulmonary aspergillosis (ABPA) and asthma (3 arms), sponsored by Pulmatrix, Inc. Primary endpoint: Incidence of treatment-emergent adverse events. Started Oct 2022; status: terminated.
02
Drugs
Pulmazole
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)asthma
Beyond the preview
Go deeper on 2022-002289-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002289-33.